We set out to investigate IMRT-based concomitant boost. Eight patients with stage III/IV squamous cell carcinoma of the head and neck treated with once daily with chemoradiotherapy at the Dana-Farber/Brigham and Women's Hospital had their treatment plans reviewed with IRB approval. Each case was replanned for treatment with a a concomitant boost regimen. Plans delivered 1.9 Gy in 30 fractions to 57 Gy with a boost of 1.5 Gy in 10 fractions for a total dose of 72 Gy. The boost was planned with both IMRT and 3-D conformal, to compare the two techniques. For each patient, both plans (IMRT-IMRT and IMRT-3DCRT) were evaluated for target and avoidance coverage, monitor units and integral dose. Finally, we evaluated the plans for time to completion. The IMRT-IMRT and IMRT-3-DCRT techniques were equivalent for target coverage. 100% coverage of the GTV and PTV was achieved with 97% of the prescription dose. Hot spots were seen 104% to 108% with IMRT-IMRT plan and from 102-111% with the IMRT-3DCRT plans. The IMRT-IMRT boost had double the monitor units as the 3-DCRT boosts. When the total monitor units from both the initial and boost portions of the plans were e combined there was not a significant differnce. There was a slight increase in integral dose with the IMRT-IMRT plans of mean 3.8%. Planning time was increased for the 3-DCRT boost as opposed to the IMRT boost (mean 3.5 hours vs. 1.5 hours). More time was needed for quality assurance of the IMRT-IMRT plans (3.0 hours vs.
Introduction
Altered fractionation has become a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN). It has long been known to improve local control by 10% over standard fractionation (1) . Recently, it has also been shown to improve overall survival (2). However, with the added benefits in local control, come increases in acute and late toxicity (1, 2). These toxicities not only impact the patient's quality of life but can also result in treatment breaks, which may decrease the tumor control probability. Treatment breaks are even more likely if altered fractionation is combined with systemic therapy (3) .
Parallel to developments in altered fractionation has been the development of a novel technology for radiotherapy delivery, intensity modulated radiotherapy, or IMRT. IMRT allows for differential dose painting that, in the head and neck, corresponds to traditional methods of cone downs utilized in conventional treatment. IMRT has shown the ability to allow for sparing of salivary glands, muscles of swallowing as well as larynx and oral cavity (4-7). These advances have led to improvements in quality of life for patients with SCCHN.
Technology in Cancer Research & Treatment, Volume 7, Number 6, December 2008 However, IMRT is technically more complicated than traditional techniques and requires increased time and resources in planning and delivery. These obstacles are generally considered worthwhile for once a day treatments, because of the benefits of IMRT, but are problematic for twice a day treatments that may require multiple IMRT plans. Therefore, the radiation oncologist is faced with a dilemma: continue to use altered fractionation without IMRT or use IMRT and abandon altered fractionation. This dilemma confronted our department at DFCI and we sought out two parallel solutions a twice daily IMRT-IMRT approach and IMRT-3DCRT approach. The goal was to provide a comparison and/or roadmap for other departments facing similar challenges.
Classically, the concomitant boost regimen, developed at M.D. Anderson Cancer Center (8), employs a comprehensive treatment of the primary and nodal volumes and then adds a second afternoon fraction for cone down, which is done simultaneously over the last ten to twelve treatments. This regimen has been shown to improve local control in SCCHN (1). We have adapted this approach to an IMRT based treatment plan with two approaches. One involves two separate IMRT plans, one for the primary treatment and a second IMRT plan for the boost. The second approach utilizes a 3-D conformal approach for the boost to potentially minimize time in planning and delivery for the second IMRT fraction. For each of these approaches we sought to determine the feasibility of creating treatment plans that achieved goals of tumor volume coverage while maintaining normal tissue sparing. As a secondary endpoint we also examined the time required in planning and quality assurance for both techniques.
Materials and Methods

Case Selection
Eight patients with SCCHN were selected, who had been treated with concurrent chemoradiotherapy at the DFCI/ BWCC from 2005-2006, using once daily IMRT treatment with dose painting. For purposes of this study, they were replanned for a concomitant boost course of therapy. Two types of cases were chosen for this study. The first set (n=4) compromised stage III/IV oropharynx cancer with ipsilateral lymphadenopathy only. (Type A) It was felt that these cases would be the most common tumors treated with IMRT because of the ease of parotid sparing and may also be relatively easily approached with 3-D boost techniques because of the ipsilateral nature of the disease. The second type of cases (n=4; Type B) were cases with either bilateral lymphadenopathy or primary sites in the oral cavity or larynx which were felt to be more challenging to plan with either technique. Table I lists the clinical details of the cases selected.
Dose Fractionation Scheme
Multiple altered fractionation schemes are currently in use for SCCHN. We chose to investigate a variation of the standard concomitant boost regimen outlined by MD Anderson Cancer Center (8). In this regimen the patient receives once daily therapy for the first 18 fractions at a dose of 1.8 Gy and then begins a concomitant afternoon fraction cone down treatment of 1.5 Gy for a total of 72 Gy over six and half weeks. This approach combines elements of accelerated treatment with hyperfractionation. For IMRT treatment we used a variant of that scheme, also used by MD Anderson using 1.9 Gy in 30 fractions to 57 Gy with the boost prescription of 1.5 Gy in 10 fractions for a total dose of 72 Gy.
IMRT Planning
All eight cases were planned utilizing inverse planned IMRT using ECLIPSE treatment planning system (Varian, Palo Alto CA). These plans were designed for delivery with dynamic multileaf collimators on a Varian 21EX. The dose volume constraints were standard for our typical IMRT planning and are seen in Table II . One physicist (L. W.) did all the optimizations. The initial optimization was done on the large field or a.m. plan and subsequently the optimization was performed for the boost plan. The a.m. IMRT plan used a nine equispaced field technique, whereas the p.m. IMRT fraction varied between 2-5 fields based on the planner's discretion .Patient-specific QA was carried out using a single ion chamber (Exradin A14) and film (EDR2, Kodak) placed in a solid water phantom. The departmental tolerance for the absolute dose agreement between ion chamber and calculation is 3%. Relative dose distributions were compared by overlaying the calculated and measured isodose curves using RIT4 software (RIT, Colorado Springs, CO). Dosimetric and spatial accuracy of our IMRT planning and delivery has been independently verified using the anthropomorphic head phantom from the Radiological Physics Center (Houston, TX).
Target Coverage and 3-D Conformal Planning
The A.M. volume PTV_54 included all grossly involved primary sites and nodal volumes as well as all subclinical nodal regions and mucosal sites at risk for disease. The PTV_72 was the target for the boost portion of the treatment. It was defined as the grossly involved primary site and pathologic nodes defined by CT and FDG-PET with a 5 mm expansion for setup uncertainty. The normal tissue avoidances were spinal cord, parotids, and oral cavity. In all eight patients, one physicist (L. W.) created an alternative to the P.M. fraction with IMRT using 3-D CRT techniques. There was not a specific template or strategy for these plans as they were varied cases and left up to the discretion and expertise of the treatment planner. As with IMRT the goals of this planning was to cover the identical boost volume and preserve the normal tissue constraints. The full details of the planning objectives can be seen in Table II .
Plan Review and Evaluation
After the planning was completed, both the IMRT and 3-D CRT plans were reviewed by one physician (A. M. A) to ensure that it met the clinical objectives and would be clinically acceptable for treatment. The two techniques were then compared for GTV, PTV coverage, and normal tissue sparing including parotids and oral cavity doses. The two techniques were also compared for overall planning time and monitor units.
Results
Target Coverage
As target coverage was the primary objective it is not surprising that both the IMRT-IMRT technique as well as the IMRT-3D technique achieved excellent target coverage. The results for GTV, CTV, and PTV coverage are illustrated in Table III . Figure 1 shows an example of the isodose differences seen between 3-DCRT and IMRT boosts plans.
Normal Tissue Sparing
Normal tissue sparing was equivalent for the two techniques. Cord tolerance was the primary avoidance constraint and, as expected, this was easily achieved with both techniques. Parotid sparing and oral cavity sparing was also achieved with equal success with both 3-D and IMRT techniques. The detailed results of the organs at risk can be seen in Table IV .
Monitor Units and Integral Dose
The monitor units, as expected, were approximately double for IMRT boost as opposed to 3-D CRT boosts. The full data is shown in Table IV . In reference to the integral dose, the patients from group A, the IMRT-3D plan gave local integral dose 1.5% higher than the IMRT-IMRT plan. For the patient from group B, the IMRT-IMRT plan gave local integral dose 3.8% higher than the IMRT-3D plan. These are absolute differences and are not statistically significant.
Time in Planning and Delivery and Quality Assurance
We tracked the planning time for the physicist and also combined that with the Q/A time. The IMRT boost took an average of 1.5 hours of planning time, compared with 3.5 hours 3-DCRT boost. The quality assurance time was doubled for the IMRT-IMRT plans (3.0 hours vs. 1.5 hours for IMRT-3-DCRT). The treatment delivery time was similar for both approaches. 
Discussion
The junction of technology and clinical trials is a subject of difficulty in radiation oncology. This is particularly apparent in the management of squamous cell carcinoma of the head and neck. Data have accrued over the past 20 years showing benefits to local control in SCCHN with altered fractionation (1, 9, 10) . At the same time, the technology of IMRT has been developed with the benefits of improved targeting as well as sparing of critical normal tissues. The question that needs to be addressed is can we or should we combine these two important advances? Here we focus on one aspect of the problem -what are the advantages and disadvantages of planning the boost portion of a concomitant boost treatment program as either IMRT or with 3-D conformal techniques.
IMRT has shown the ability to maintain excellent local control with once a day radiotherapy with results reported in the nasopharynx and oropharynx (11) (12) (13) . In addition, it has been shown to decrease the toxicities of xerostomia (6, 7, 14) and potentially decrease swallowing toxicities (5). These benefits have been achieved with once daily therapy. If we combine these two approaches, some of the standard techniques for IMRT are not used (such as differential dosing) and therefore require a reexamination of the utility of such IMRT plans. Among many concerns, combining IMRT with a twice-daily schedule requires increased machine time, physicist time, and may be difficult to plan accurately.
An alternative approach to twice daily IMRT is a simultaneous integrated boost technique or SIB-IMRT. This technique employs dose-painting to deliver doses in excess of 2 Gy per fraction to the gross disease thereby attempting to mimic the acceleration of treatment achieved with altered fractionation (13, 15, 16) . While this approach may prove to be acceptable, and indeed because of the IMRT-based delivery and dosing strategy deliver a plan with higher conformality as compared to conventional altered fractionation regimens, there are only forty cases currently reported in the world literature with this technique. This compares with the thousands treated with the accepted altered fractionation regimens; clearly more data is needed. In particular, we are concerned with that the basic tumor biology, which is taken advantage of with two daily fractions, may not be translated in the SIB regimen which uses one daily fraction. In addition, the SIB regimens generally give 2.4-2.6 Gy per day, which is less than the 3.3 Gy delivered during the boost portion of the concomitant boost regimen. Although this higher dose per day is only given in the final week and half of treatment, based on radiobiological models, it is exactly this time in which accelerated repopulation occurs. In addition, SIB gives the entire dose at one time and also does not allow for normal tissue repair with the entire dose delivered simultaneously. For these reasons we sought to integrate the historical data for altered fractionation with the new technology of IMRT. Furthermore, in the future when combined IMRT-IMRT altered fractionation schedules are compared to SIB one must evaluate not only the cumulative DVH's but the "biological" DVH's that take into account the difference in hot or cold spots as delivered BID vs. QD. The current planning study looks at how to achieve this -time is clearly a factor, but what is the best way?
In our study, we demonstrated that planning cases with concomitant boost IMRT is feasible and results in no decrease in the ability to deliver target doses or spare normal tissues. Our results show that using either a 3-D conformal boost or IMRT boost achieves similar results. One limitation of our results is that we did not include any nasopharyngeal cases as these are rarely treated with altered fractionation. Consequently, we cannot conclude that the 3-D and IMRT boosts are equivalent near the base of skull. However, we feel that the 3-D conformal boost success is highly operator dependant, meaning it relies on the expertise of the planner, and may often require more planning time than IMRT-IMRT approach. To our knowledge only one group has specifically published on the use of IMRT-IMRT based concomitant boost approach with clinical results. Shoenfeld et al. reported on the outcome of 100 patients treated with altered fractionated IMRT at the University of Florida and demonstrated that this approach results in good local control with out any increased toxicity (17). Clearly, other studies are needed but perhaps with the adoption of IMRT we do not need to abandon traditional but successful models of treatment such as concomitant boost radiotherapy.
One concern that exists with our approach of IMRT-IMRT concomitant boost is the increases monitor units and integral dose to the patient. Hall et al. has already raised the specter of increase risk of second malignancies with IMRT (18, 19) . This is a concern to the field in general but may be outweighed by the improvement in tumor coverage and or toxicity avoidance. However, once the decision to treat the first fraction with IMRT is made an additional second IMRT fraction is unlikely to increase these risks
Conclusion
IMRT based concomitant boost is feasible to plan and deliver. It offers the advantage of supporting multiple clinical trials that have shown a benefit to altered fractionation while still maintaining the ability to preserve normal tissues constraints. We therefore, recommend either the 3D-IMRT or IMRT-IMRT technique depending on the time constraints and expertise of the planners in each department. This approach can be used as a reasonable alternative in future trials that require the use of altered fractionation.
